ALIVUS vs GLENMARK: Stock Comparison
GLENMARK PHARMACEUTICALS is the larger company by market capitalisation. ALIVUS LIFE SCIENCES shows a lower P/E, a higher ROE and a higher net margin, while GLENMARK PHARMACEUTICALS shows a higher dividend yield, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ALIVUS leads 6; GLENMARK leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ALIVUS | GLENMARK |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ALIVUS | GLENMARK |
|---|---|---|
| Live Price | ₹1,366.3 | ₹2,437.2 |
| Day Change | -3.7% | -0.89% |
| Volume | 1.7 L | 4.13 L |
| 52-Week High | ₹1,493.8 | ₹2,537.6 |
| 52-Week Low | ₹819 | ₹1,792.6 |
| Distance from 52W High | -8.54% | -3.96% |
Valuation
| Metric | ALIVUS | GLENMARK |
|---|---|---|
| Market Cap | ₹16,771 Cr | ₹68,490 Cr |
| P/E Ratio | 28.86x | 46.23x |
| P/B Ratio | 5.22x | 6.58x |
| EPS | ₹13.04 | ₹26.07 |
| Book Value | ₹271.48 | ₹372.49 |
| Dividend Yield | 0% | 0.21% |
Growth
| Metric | ALIVUS | GLENMARK |
|---|---|---|
| Revenue Growth (TTM YoY) | 6.1% | 14.3% |
| EPS Growth (TTM YoY) | 14.5% | 6,575% |
| Qtr Sales Growth | -7.07% | -39.41% |
| Qtr Profit Growth | -1.59% | 52.36% |
Profitability & Leverage
| Metric | ALIVUS | GLENMARK |
|---|---|---|
| ROE | 16.94% | 12.96% |
| ROCE | 17.13% | 18.25% |
| Net Margin | 22.05% | 8.15% |
| Operating Margin | 29.65% | 12.92% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ALIVUS | GLENMARK |
|---|---|---|
| Promoter Holding | 74.87% | 46.65% |
| FII Holding | 5.54%▲ 0.25 pp | 20.89%▲ 0.55 pp |
| DII Holding | 7.18%▼ 0.1 pp | 18.6%▼ 0.69 pp |
| Public Holding | 12.41%▼ 0.15 pp | 13.81%▲ 0.13 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ALIVUS LIFE SCIENCES and GLENMARK PHARMACEUTICALS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.